US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SDEV $7.48 ▲+0.00% SPCX $158.96 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00%
FinancialContent

Articles published by Olema Oncology

< Previous 1 2 3 4 Next >
News headline image
Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology Reports Third Quarter 2025 Financial and Operating Results
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer
From Olema Oncology
Via GlobeNewswire
Tickers OLMA PFE
News headline image
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology Reports Second Quarter 2025 Financial and Operating Results
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology Reports First Quarter 2025 Financial and Operating Results
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
News headline image
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
< Previous 1 2 3 4 Next >